Abbott Laboratories (NYSE: ABT) and Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.
This table compares Abbott Laboratories and Adamis Pharmaceuticals Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Adamis Pharmaceuticals Corporation||-158.51%||-69.03%||-47.51%|
Abbott Laboratories pays an annual dividend of $1.06 per share and has a dividend yield of 1.9%. Adamis Pharmaceuticals Corporation does not pay a dividend. Abbott Laboratories pays out 149.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories has increased its dividend for 44 consecutive years.
Insider and Institutional Ownership
71.5% of Abbott Laboratories shares are held by institutional investors. Comparatively, 10.1% of Adamis Pharmaceuticals Corporation shares are held by institutional investors. 0.8% of Abbott Laboratories shares are held by company insiders. Comparatively, 9.6% of Adamis Pharmaceuticals Corporation shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Abbott Laboratories has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals Corporation has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500.
Valuation and Earnings
This table compares Abbott Laboratories and Adamis Pharmaceuticals Corporation’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Abbott Laboratories||$23.61 billion||4.03||$5.14 billion||$0.71||77.06|
|Adamis Pharmaceuticals Corporation||$11.39 million||14.04||-$18.97 million||N/A||N/A|
Abbott Laboratories has higher revenue and earnings than Adamis Pharmaceuticals Corporation.
This is a breakdown of recent ratings and recommmendations for Abbott Laboratories and Adamis Pharmaceuticals Corporation, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Adamis Pharmaceuticals Corporation||0||0||3||0||3.00|
Abbott Laboratories currently has a consensus target price of $55.50, indicating a potential upside of 1.44%. Adamis Pharmaceuticals Corporation has a consensus target price of $9.83, indicating a potential upside of 92.81%. Given Adamis Pharmaceuticals Corporation’s stronger consensus rating and higher probable upside, analysts clearly believe Adamis Pharmaceuticals Corporation is more favorable than Abbott Laboratories.
Abbott Laboratories beats Adamis Pharmaceuticals Corporation on 10 of the 15 factors compared between the two stocks.
Abbott Laboratories Company Profile
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company’s Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.
Adamis Pharmaceuticals Corporation Company Profile
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.